A Phase I/II Trial to Assess the Tolerability of RAD 001 [everolimus] With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer

Trial Profile

A Phase I/II Trial to Assess the Tolerability of RAD 001 [everolimus] With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Everolimus (Primary) ; Gefitinib
  • Indications Glioblastoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2015 Results published in the Cancer.
    • 02 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top